This obesity-drug startup emerged from stealth with $290 million and plans to take on Wegovy and Zepbound 

Metsera is taking a ‘Lego kit’ approach to finding a next-generation weight-loss treatment.

Biopharma startup Metsera turned heads in April when it emerged from stealth, announcing $290 million in funding from prestigious backers—an all-star roster of scientists and executives—and a portfolio of drug assets all focused on what may be the most lucrative pharmaceutical opportunity ever: obesity.